focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Its out? I missed it?
I was on holiday in Bologna region - and didn't have great wifi for most of the time - an annual report came out and share price hasn't dropped 30 or 40 per cent? I am very much looking forwards to read it.
And having just got back I would heartily recommend a visit Bologna - its very exciting to walk around the endless arcades in the centre of the city and if you want some peace and quiet in the same region then Orvieto, Assisi and Ravenna are quiet, beautiful places. Anyway off to read the report and quite pleased the share price hasn't collapsed - which, to be honest, was what I imagined would happen.
FDA submission review 3 months fir RPD submission , no amendments from 16/02 submission.
What a surprise...TB pays himself £100k to take from the pockets of the PI's by trashing the price selling high and taking them back lower...couldn't make it up. He must be grinning like a Cheshire cat. If that's not a 2 fingered salute to the rest of us then what is?
Trevor brown and his cronies have decimated share price and he has been paid 100k on top of this.
I wonder what the browns have taken out of here with their share sales in last 18 months.
What percentage of votes do shareholders need to get him removed?
Gee ,
As response expected mid May I presumed this was the 16/2 application 🤷🏼♂️ but you may be right with 3rd time lucky .
Max third time they have applied! Reapplied 16/2 and they must have reapplied since then, so third time lucky but it does not install confidence in what they are doing IMO but every one has to make their own conclusions.
Gee
PRD application goalpost change .
Application was changed on advisory from FDA it’s not changed again response expected mid May
Morning, results just show IB are chronically under funded and it will be 2025 before we get any real traction hence TB comment judge me in 2 years re share price, disappointed PRD goal post have changed again re application, TB taking £100k salary also poor considering what he has done to SP this year.
To be fair, GE agreement was late August so won’t have much impact on 2023 figures.
I think the results are in line and it’s still good at controlling the costs.
There is an IB Zero. update ( or Downdate ? ) in the Report
IB Zero was to novel so they was asked to reapply in a different heading a year ago but we have heard nothing, did they reapply.
Cautious
No I will not stop going on about PRVs as it is very relevant. No I am not on the payroll
Zero we already know about, it has all been in previous RNS’s
I will continue to try and be honest with what I post, the good, bad and neutral. Max picked up on something which could have a big impact on the future of the company so I commented on it. Cautious you can block me if you want that is your choice as well.
Thanks, have a good day everyone
Tyke will you give up banging on about Prv’s. Constant 100-200 million and what was your forecast 50-100p per share. You’re not on Browns payroll are ya! ( seriously let’s be realistic)
Why isn’t the imaging doing more revenue, in with Bayer ( apparently global ) and GM but not seeing any benifits Why. I was under the impression we were waiting for FDA approval so the imaging could be more widely spread through out the USa, there was one submitted in May 22 Fda510k for IBzeroG, does anybody know what’s happening with that application
There’s no significant increase in revs from IB. Given that its software has been embedded in our OEM Kit I have no idea from the financials wtf TB doing for it! Revs are actually down!
This still a jam tomorrow story with chances of high returns that hooks investors in!
Usual caveats
Trek
Just picking up on something Max noticed. 2 PRD applications can mean 2 PRV’s. So in theory possibly $200m+ which would have to be before end of 2026. Now that would be nice.
We can all dream
Thanks
This was from the mid year update last year, “More than 45 different hospitals and healthcare systems are at varying stages of evaluating our software, with more sites entering the sales pipeline. This step-change in pre-sales activity is approximately a seven-fold increase over previous periods and is due, in large part, to the traction gained from our platform partners including TeraRecon (Eureka) and Bayer (Calantic). These partners have the medical expertise and marketing reach to sell our technologies into large existing installed customer bases and have ample sales and marketing resources to win clients.
It is a relatively easy up-sell for IB's partners' sales teams to activate IB's technology on platforms already being used clinically. The number of sites evaluating our software continues to increase. Thus, we are optimistic about the revenue activity and anticipate a step-change starting in the 2nd half of 2023.”
Where is the step change via easy up sells?
Sales have increased but I would say no where near what we hoped for.
No comment on share price
Stonechecker seems to be non existent now and written off.
Only good news I can see is that we are looking at the global market now not just USA.
I would see very neutral set of results regarding effect on the share price. Hopefully in May we do get some good news.
Oh well, let’s see how TB try to sway shareholders, I expect a few RNSs in the next month just so he can be positive at the AGM.
Thanks
You could argue that my dead dog could do a better job than what he’s doing from his care home.
I also noticed the lack of mention of big pharma around phase 2 talk. That was just a big lie to entice mugs like us to buy the placing being forward sold in my opinion.
Next up is the agm and I’m sure this year we will have to vote to reappoint him as the ceo. He’s not getting my vote. He’ll probably fudge it so ensure he gets reappointed but it would be fun to make him sweat abit if enough of us say no!!
Just from IQAI though ... he has his other companies that he milks
-- BB--
Who puts out an annual financial report at 3.25pm on a Monday?
Probably waited all last week for someone really famous to die to slip it out unnoticed.
I see that TB still takes his £100,000 a year.
Have you not seen the cost of living in Switzerland, bet they don't have Food Banks though.
So no mention of a large pharmaceutical maybe getting involved with phase 2 even though he was plugging that a while back. It states see video link re phase 1 and Eap, were is that
Who puts out an annual financial report at 3.25pm on a Monday. Knob
Goalposts appear to keep changing with PRD application, to be honest a long way to go, they cant be bothered to put results in a RNS, that says a lot, no shareholders letter unless on X later on.
No Fireworks!
Now we have 2 RPD designations on review with news hopefully in May .
Narrowed the odds slightly
Outlook
The new financial year has started off well, and revenue to date is higher than the comparable period in 2023. If this trend continues, we expect to exceed last year's revenue.
Does he mean personally or the company. Again lots of ifs and but. Doesn’t really justify screwing everyone over at the beginning of the year. Funny how they said the proceeds of the placing was going towards the eap now they’re saying their begging charities for it.